ALX Oncology Holdings Inc Investor Relations Material
Latest events
Study Result
ALX Oncology Holdings Inc
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from ALX Oncology Holdings Inc
Access all reports
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that target the CD47 checkpoint pathway, which plays a critical role in cancer cells' ability to evade the immune system. The company's lead product candidate, evorpacept, is designed to block CD47 and is being developed in combination with other anti-cancer agents. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for ALX Oncology Holdings Inc
Corporate Presentation
ALX Oncology Holdings Inc
Corporate Presentation
ALX Oncology Holdings Inc
Latest articles
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
The Toyota Way: Revolutionizing Global Manufacturing
Explore how Toyota's Lean Manufacturing and Kaizen principles revolutionized production and quality, setting global benchmarks for excellence.
2 Sep 2024
Ticker symbol
ALXO
Country
🇺🇸 United States